Kidron Nadav reported grant involving 629,000 shares of ORAMED PHARMACEUTICALS INC. on Nov 12, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
President and CEO
President and CEO
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
629,000Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
4,769,505Direct
Trade date
Nov 12, 2026Grant
Filed
Nov 13, 2026, 9:11 PM ET2-day reporting delay
Accession
0001213900-26-120035Code A · Transaction 401540
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Grant688,000——Trade 401541
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ORMP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORMP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +1.5%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 629,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited. F2: On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 688,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.